Quimioterapia e anestesia

Márcio Augusto Lacerda

doi:10.1590/S0034-70942001000300009

Review Article

Quimioterapia e anestesia

Chemotherapy and anesthesia

Márcio Augusto Lacerda

http://dx.doi.org/10.1590/S0034-70942001000300009 Braz J Anesthesiol, vol.51, n3, p.250-270, 2001

PDF

Downloads: 4

Resumo

JUSTIFICATIVA E OBJETIVOS: A quimioterapia é um dos principais tipos de tratamento oferecido a pacientes com câncer, mas ainda causam importantes efeitos colaterais, reversíveis ou não. Para os anestesiologistas, conhecer estas drogas, complicações e interações medicamentosas, é de importância capital em cirurgias com pacientes em tratamento de neoplasias. CONTEÚDO: Nesta revisão apresentam-se os diferentes tipos de quimioterápicos atualmente utilizados, a classificação farmacológica, repercussões orgânicas, interações com outras substâncias, e a conduta anestésica mais apropriada frente a elas, objetivando reduzir a morbi-mortalidade perioperatória nestes pacientes. CONCLUSÕES: O conhecimento, pelo anestesiologista, das formas de tratamento, das características farmacológicas destas substâncias, seus efeitos adversos, lesões estruturais e possíveis interações medicamentosas por elas geradas e potencializadas pelas várias técnicas anestésicas hoje empregadas, pode certamente reduzir a morbi-mortalidade peri-operatória destes pacientes.

Palavras-chave

DROGAS, Interação: quimioterápicos

Abstract

BACKGROUND AND OBJECTIVES: Chemotherapy is one of the main treatment available for cancer patients, but is still causing important side effects, reversible or not. Knowing such drugs, complications and interactions is critical for the anesthesiologist during surgeries in patients under cancer treatment. CONTENTS: This review presents the different types of chemotherapy agents currently used, their pharmacological classification, organic repercussions, interactions with other drugs and the most adequate anesthetic technique aiming at decreasing perioperative morbidity and mortality. CONCLUSIONS: The anesthesiologist awareness of types of treatment, pharmacological properties of such substances, their adverse effects, structural lesions and possible drug interactions created by them and exacerbated by several current anesthetic techniques may certainly decrease perioperative morbidity and mortality.

Keywords

DRUGS, Interation: chemotherapic

References

Câncer no Brasil: Dados dos Registros de Câncer de Base Populacional. 1991;I.

Câncer no Brasil: Dados dos Registros de Câncer de Base Populacional. 1995;II.

Robinson PN. Chemotherapy and Anaesthesia. Anaesthesia and Malignant Disease. 1996:19-22.

Weiss GR. Chemotherapy. Clinical Oncology. 1995:97-109.

DeVita VT. Principles of Chemotherapy in Cancer. Principles and Practices of Oncology. 1995:257-286.

Stoelting RK. Chemotherapeutic Drugs. Pharmacology and Physiology in Anesthetic Practice. 1998:490-505.

Chabner BA, Myers CE. Clinical Pharmacology of Cancer Chemotherapy in Cancer. Principles and Practices of Oncology. 1995:287-328.

Chabner BA, Allegra CJ, Curt GA. Antineoplastic Agents. Goodman and Gilman: The Pharmacological Basis of Therapeutics. 1996:1233-1288.

Chabner BA, Donehower RC, Schilsky RL. Clinical pharmacology of methotrexate. Cancer Treat Rep. 1981;65:51-54.

Chung F. Cancer, chemotherapy and anaesthesia. Can Anaesth Soc J. 1982;29:364-371.

Selvin BF. Cancer chemotherapy: implications for the anesthesiologist. Anesth Analg. 1981;60:425-434.

Borgeat A, Chiolero R, Baylon P. Perioperative cardiovascular collapse in a patient previouly treated with doxorubicin. Anesth Analg. 1988;67:1189-1191.

Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med. 1991;324:843-845.

Gottdiener JS, Appelbaum FR, Ferrans VJ. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758-763.

Talcott JA, Herman TJ. Acute ischemic vascular events and cisplatin. Ann Intern Med. 1987;107:121-122.

Blom-Muilwijk MC, Vriesemdorp R, Veninga TS. Pulmonary toxicity after treatment with bleomycin along or in combination with hyperoxia: Studies in the rat. Br J Anaesth. 1988;60:91-97.

Goldiner PL, Carlon G, Cvitkovic E. Factors influencing postoperative morbidity and mortality in patients treated with bleomicyn. BMJ. 1978;1:1664-1667.

Hulbert JC, Grossman JE, Cummings KB. Risk factors of anesthesia and surgery in bleomicyn-treated patients. J Urol. 1983;130:163-164.

Mathes DD. Bleomicyn and hyperoxia exposure in the operating roon. Anesth Analg. 1995;81:624-629.

Jackson SH, Barker SJ. Methemoglobinemia in a patient receiving flutamide. Anesthesiology. 1995;82:1065-1067.

Redding SW. Oral Considerations of Cancer Chemotherapy. Internal Medicine for Dentistry. 1989.

Narins RG, Carley M, Bloom EJ. The nephrotoxicity of chemotherapeutic agents. Semin Nephrol. 1990;10:556-564.

Zsigmond EK, Robins G. The effect of a series of anticancer drugs on plasma cholinesterase activity. Can Anaesth Soc J. 1972;19:75-82.

Freitas LC, Raposo LCM, Finoquio RA. Instalação, manutenção e manuseio de cateteres venosos centrais de inserção periférica em pacientes submetidos a tratamento quimioterápico. Rev Bras Cancerol. 1999;45:1.

Consenso sobre tratamento e profilaxia de trombose venosa profunda. 1998:105-109.

Recommendations for neuroaxial anesthesia and anticoagulation. 1999.

Malkowicz SB, Wein A. Prostate Cancer. Internal Medicine. 1998:1220-1229.

Câncer no Brasil: Protocolos de Tratamento: Quimioterapia 01/2000. 2000.

Mihalo RM, Cagle CK, Cronau LH. Preanesthetic evaluation of the cancer patient. Cancer Bull. 1995;4:8-12.

Quimioterapia e anestesia

Chemotherapy and anesthesia

Márcio Augusto Lacerda

Resumo

Palavras-chave

Abstract

Keywords

References

Links

Share

Braz J Anesthesiol